News


June 24, 2013

Leading Cardiovascular Researchers Present Promising Bendavia Findings at 2013 European Society of Cardiology Heart Failure Congress

BOSTON, MA, June 24, 2013—(BUSINESS WIRE)—Stealth Peptides Inc. (Stealth) reported today on promising Bendavia™ findings presented by leading cardiovascular researchers at the European Society of Cardiology (ESC) Heart Failure Congress. Several researchers from Europe and the United States, including Drs. … Continue reading


January 22, 2013

Stealth Peptides Reports Successful Clinical Study of Oral Bendavia

Positive Data Broadens Bendavia’s Potential for Chronic Heart Failure and Cardioprotection BOSTON, MA, January 22, 2013–(BUSINESS WIRE)– Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies for cardiovascular disease and its complications, announced today positive oral … Continue reading


January 16, 2013

Stealth Peptides Initiates Patient Enrollment for Novel Treatment of Acute Kidney Injury

Clinical Study Broadens Bendavia’s Potential for Acute and Chronic Kidney Disease BOSTON, MA, January 16, 2013–(BUSINESS WIRE)– Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative therapies for cardiovascular and renal disease, announced today that the first patient … Continue reading


November 26, 2012

Drs. Hani Sabbah, David Brown, Sharon Hale and Robert Kloner Present Bendavia Research at 2012 American Heart Association Annual Meeting

BOSTON, MA, November 26, 2012—(BUSINESS WIRE)—Stealth Peptides Inc. (Stealth) reported today on promising Bendavia™ findings presented by leading cardiovascular researchers at the American Heart Association’s (AHA) annual meeting. The researchers, including Drs. Hani Sabbah, David Brown, Sharon Hale and Robert Kloner … Continue reading


November 19, 2012

Top Researchers Present Promising Bendavia Findings at Annual American Society of Nephrology Meeting

BOSTON, MA, November 19, 2012–(BUSINESS WIRE)–Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies for diseases with unmet medical needs, reported today on Bendavia™ study findings presented during the annual American Society of Nephrology (ASN) meeting. … Continue reading


November 2, 2012

Stealth Peptides Co-Sponsors Cardioprotection Colloquium

BOSTON, MA, November 2, 2012—Stealth Peptides co-sponsored the 2012 Cardioprotection Colloquium held at the University of California at Los Angeles today, which preceded the American Heart Association Scientific Sessions 2012. This Colloquium featured the latest innovations in cardioprotection and the … Continue reading


June 25, 2012

Stealth Peptides Initiates Patient Enrollment for Novel Treatment of Cardiovascular Disease and Reperfusion Injury

BOSTON, MA, June 25, 2012–(BUSINESS WIRE)–Stealth Peptides Incorporated (Stealth), a privately held biopharmaceutical company developing innovative therapies for cardiovascular disease and its complications, announced today that the first patient was enrolled in its multinational Phase II clinical study with Bendavia™ … Continue reading


April 9, 2012

Stealth Peptides Inc. Reports Results from Phase I Clinical Drug Interaction Studies with Bendavia

BOSTON, MA, April 9, 2012–(BUSINESS WIRE)–Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative therapies for diseases with unmet medical needs, announced today the results from three Phase I clinical trials of Bendavia, a novel compound that targets … Continue reading


November 28, 2011

Dr. Robert Kloner Presents Bendavia Research At 2011 American Heart Association Annual Meeting

BOSTON, MA, November 28, 2011—(BUSINESS WIRE)—Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies for diseases with unmet medical needs, reported today on a presentation of Bendavia study findings by cardiologist Dr. Robert Kloner, who presented … Continue reading


November 15, 2011

Researchers Present Promising Bendavia Findings at Annual American Society of Nephrology Meeting

BOSTON, Massachusetts, November 15, 2011–(BUSINESS WIRE)–Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies for diseases with unmet medical needs, reported today on Bendavia study findings presented during the annual American Society of Nephrology (ASN) meeting. … Continue reading


October 7, 2011

BioWorld Today Spotlights Stealth Peptides and Bendavia

BioWorld Today featured Stealth Peptides and Bendavia in a cover story headlined “Stealth Moves Mitochondrial Candidate into Phase II Trials,” and previewed the upcoming EMBRACE-STEMI study, a Phase II clinical trial in the U.S. and Europe for patients experiencing acute … Continue reading


August 1, 2011

Bendavia Presented at 2011 American Heart Association’s Cardiovascular Scientific Sessions

BOSTON, MA, August 1, 2011–(BUSINESS WIRE)–Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies for diseases with unmet medical needs, presented its lead clinical candidate, Bendavia™, during the 2011 American Heart Association’s (AHA) Cardiovascular Scientific Sessions. … Continue reading


June 27, 2011

Stealth Peptides Inc. Announces Results from Renal Impairment Clinical Study

BOSTON, MA, June 27, 2011–(BUSINESS WIRE)–Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies, announced today the results of a Phase I renal impairment study with Bendavia™. Bendavia is a novel compound that targets the mitochondrion … Continue reading


April 20, 2011

Stealth Peptides’ Bendavia Introduced During Experimental Biology 2011 Meeting

BOSTON, MA, April 20, 2011–(BUSINESS WIRE)–Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies, introduced its lead clinical candidate, Bendavia™, a novel compound that targets the mitochondrion, during multiple scientific sessions of the Experimental Biology 2011 … Continue reading


April 4, 2011

Stealth Peptides Inc. Announces Results from Healthy Volunteers Phase I Clinical Study with Bendavia™

BOSTON, MA, April 4, 2011–(BUSINESS WIRE)–Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative therapies, announced today the results of a healthy volunteers Phase I clinical study of Bendavia™, a novel compound that targets the mitochondrion to treat … Continue reading


November 22, 2010

Bendavia™ Presented at 2010 American Heart Association’s Scientific Sessions

BOSTON, MA, November 22, 2010–(BUSINESS WIRE) Stealth Peptides, a privately held biopharmaceutical company developing innovative mitochondrial therapies for diseases with significant unmet medical needs, introduced its lead clinical candidate, Bendavia™, a novel compound that targets the mitochondrion, at the 2010 … Continue reading


November 8, 2010

Bendavia Recognized as One of Windhover’s Top 10 Cardiovascular and Metabolic Programs to Watch

BOSTON, MA, November 8, 2010–(BUSINESS WIRE) Stealth Peptides, a privately held biopharmaceutical company developing innovative mitochondrial therapies for diseases with significant unmet medical needs, announced today that its lead clinical candidate, Bendavia™, a novel compound that targets the mitochondrion to … Continue reading


September 13, 2010

Stealth Peptides Inc. Announces Clinical Phase I Results With Bendavia™ Demonstrating Safety and Tolerability With Highly Predictable Pharmacokinetics

BOSTON, MA, September 13, 2010–(BUSINESS WIRE) Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative therapies, announced today the results of its first-in-humans Phase I clinical trial of Bendavia™, a new chemical entity that targets mitochondria to treat … Continue reading


June 14, 2010

Stealth Peptides Inc. Completes Initial Phase I Clinical Trial Cohort with Bendavia™, a Mitochondrial Targeted Therapy for Ischemia Reperfusion Injury

Boston, MA, June 14, 2010 –(BUSINESS WIRE) Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative therapies, announced today that it concluded its initial Phase I clinical trial cohort of a first-in-humans study with Bendavia™, a compound that … Continue reading


May 17, 2010

Stealth Peptides Inc. Announces FDA IND Approval for Conduct of Clinical Studies with Bendavia™, A Mitochondrial Targeted Therapy for Ischemia Reperfusion Injury

Boston, MA, May 17, 2010–(BUSINESS WIRE) Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative therapies, announced today that the U.S. Food and Drug Administration (FDA) approved its Investigational New Drug (IND) application for Bendavia™. Bendavia is a … Continue reading


April 8, 2010

Stealth Peptides Development Roundup

Boston, MA, April 8, 2010—Stealth Peptides is a biopharmaceutical company developing novel and innovative mitochondrial targeted therapies for diseases with clear unmet medical needs including those within the cardiovascular, renal and metabolic areas.   Stealth has a rich and promising … Continue reading